(2022). Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. Bmj, 379, e071380. http://doi.org/10.1136/bmj-2022-071380
. L. Azoulay
First name
L.
Last name
Azoulay
(2022). Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Res Clin Pract, 192, 110094. http://doi.org/10.1016/j.diabres.2022.110094
. (2022). Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths. J Affect Disord, 318, 231-237. http://doi.org/10.1016/j.jad.2022.08.094
. (2022). Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care. http://doi.org/10.2337/dc22-1174
. (2022). Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc22-0712
. (2022). Menopausal Hormone Therapy Formulation and Breast Cancer Risk. Obstet Gynecol, 139, 1103-1110. http://doi.org/10.1097/aog.0000000000004723
. (2022). Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study. Bmj Open, 12, e057510. http://doi.org/10.1136/bmjopen-2021-057510
. (2022). Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study. Cancer. http://doi.org/10.1002/cncr.34208
. (2022). Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients with Type 2 Diabetes. Epidemiology. http://doi.org/10.1097/ede.0000000000001486
. (2022). Effectiveness and safety of apixaban vs. rivaroxaban in patients with atrial fibrillation and type 2 diabetes mellitus. Thromb Haemost. http://doi.org/10.1055/a-1798-2116
.